Navigation Links
Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
Date:11/1/2007

Emmy Nominated Actress Shares Her Personal Story and Tips for Better Blood

Sugar Management

BRIDGEWATER, N.J., Nov. 1 /PRNewswire-FirstCall/ -- As one of the more than 20 million Americans living with diabetes, Emmy nominated actress and Broadway star Aida Turturro is teaming up with sanofi-aventis, a world leader in diabetes care, to urge other Americans with diabetes to reach better levels of blood sugar control. Ms. Turturro's personal story can be seen in an on-line video message (http://www.AidasStory.com) where she discusses how she worked with her doctor to find the right treatment plan.

"I know how hard it can be to live your life while trying to stay in control. Whether you're acting on Broadway or just trying to get through a long workday, managing your blood sugar is a daily challenge that requires patience and support from everyone around you," said Ms. Turturro. "After more than six years, I've learned that there is no easy solution, but I'm overcoming the challenges and getting even better at managing my blood sugar."

The American Diabetes Association (ADA) encourages people with diabetes to track their blood sugar levels using an A1C test, which measures average blood glucose levels over a two- to three-month period. According to the ADA, people with diabetes should strive to keep their A1C score below seven percent.

It is estimated that approximately half of all diabetes patients in the United States are not achieving this target and, prior to taking control of her blood sugar, Ms. Turturro was one of them. "Initially, my doctor recommended diet and exercise in combination with oral medications, but I still wasn't getting my blood sugar under control. Then about five years ago, we added Lantus(R) (insulin glargine [rDNA origin] injection), a once-daily, long-acting insulin to my overall treatment plan."

The former Sopranos actress recently began using Lantus(R) SoloSTAR(R), a new, disposable insulin pen, which she says is easy to use and helps make her Lantus(R) delivery more convenient. Lantus(R) SoloSTAR(R) is the only prefilled, disposable insulin pen that allows patients to administer doses from 1 up to 80 units, in one unit increments, in one injection. The pen comes prefilled with Lantus(R), the only 24-hour insulin approved exclusively for use once a day, for the treatment of hyperglycemia in people with type 1 or type 2 diabetes.

"Taking Lantus once a day at the same time each day made an important difference in the positive way I manage my blood sugar. I found that the Lantus(R) SoloSTAR(R) pen is easy to learn, easy to use and easy to inject. It's small, discreet and convenient -- I can just throw it in my purse and take it with me during rehearsals."

By logging on to http://www.AidasStory.com, people with diabetes can find helpful hints from Ms. Turturro about working with their treating healthcare provider to decide if insulin is right for them. The website also includes a digital video featuring Ms. Turturro's personal journey to blood sugar control.

"Diabetes is not an easy disease to manage, especially without the information, tools, and support the disease demands," said Steven V. Edelman, MD, founder of the non-profit diabetes educational and motivational organization Taking Control of Your Diabetes, of which Aida Turturro is a member. "By talking about her life with diabetes, Aida inspires others to confront their own diabetes and take action with their health by looking at treatment options that may truly help them, including insulin."

For more information, please visit http://www.AidasStory.com.

About Diabetes

Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin -- the hormone needed to convert glucose (sugar) into energy. More than 230 million people worldwide are living with the disease. This number is expected to rise to a staggering 350 million within 20 years. It is estimated more than 20 million Americans have diabetes, including an estimated 6.2 million who remain undiagnosed.

At the same time, approximately half of those diagnosed are not achieving the blood sugar control target of A1C <7% recommended by the American Diabetes Association (ADA).

About Lantus(R) and Lantus(R) SoloSTAR(R)

Lantus(R) is the only 24-hour insulin approved exclusively for use once a day. Most insulins have a "peak of action," which refers to the time at which insulin reaches its maximum effect in the body. With Lantus(R), the insulin is released into the bloodstream at a relatively constant rate throughout the day and night; therefore it has no pronounced peak.

Lantus(R) SoloSTAR(R) uses a simple, intuitive design with easy-to-read display features and requires only a few steps to use it properly. Lantus(R) SoloSTAR(R) is small, discreet and eliminates the need for the patient to change cartridges.

Lantus(R) SoloSTAR(R) should be kept in cool storage (36 degrees F - 46 degrees F [2 degrees C - 8 degrees C]) until first use. Once in use, it should be kept at room temperature, as long as it remains below 86 degrees F [30 degrees C], away from direct heat or light, and can be used for up to 28 days.

Important Safety Information for Lantus(R)

Prescription Lantus(R) is for adults with type 2 diabetes or adults and children (6 years and older) with type 1 diabetes who require long-acting insulin for the control of high blood sugar.

Lantus(R) SoloStar(R) is a disposable insulin delivery device (insulin pen). Needles and the SoloStar pen must not be shared.

DO NOT DILUTE OR MIX LANTUS(R) WITH ANY OTHER INSULIN OR SOLUTION. It will not work as intended, and you may lose blood sugar control, which could be serious. Do not change your insulin without talking with your doctor. The syringe must not contain any other medication or residue. You should not use Lantus(R) if you are allergic to insulin. Lantus(R) is a long-acting insulin you inject just once a day, at the same time each day. You must test your blood sugar levels while using an insulin such as Lantus(R).

The most common side effect of insulin, including Lantus(R), is hypoglycemia, which may be serious. Other possible side effects may include injection site reactions, including changes in fat tissue at the injection site, and allergic reactions, including itching and rash. In rare cases, some allergic reactions may be life threatening. Tell your doctor about other medicines and supplements you are taking because they can change the way insulin works.

Please visit http://www.Lantus.com for full prescribing information.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.

Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

US Contacts:

Julissa Viana

Julissa.viana@sanofi-aventis.com

908-981-6575

Carrie Melia

Carrie.melia@sanofi-aventis.com

908-981-6486


'/>"/>
SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Governor tells UW to scrap network plans
2. Governor tells state, university to work together on IT
3. A disgusting video: U.S. companies sell out Americans
4. Healthcare software addresses "90 million" misclassified Americans
5. More Americans working away from the office
6. Probe into gas gouging may educate Americans about pressures on oil supply
7. The passing of Ronald Reagan, and other Americans, is a reminder of the promise of stem-cell research
8. The Best Enzyme for the Toughest PCR Challenges Improved with New Hot-Start Feature
9. Pfu DNA Polymerase as a Hot Start Alternative
10. Greater Amplification Specificity with New Hot Start PCR Enzyme
11. Improve Amplification Specificity with Hot Start PCR Enzyme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... As part ... top industry experts, and expanding its LATAM network and logistics capabilities. Enhancements ... to manage their clinical trial projects. , The expansion will provide unmatched clinical ...
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the leading provider of ... that it has been named to The Silicon Review’s “20 Fastest Growing Big Data ... Cambridge Semantics serves the needs of end users facing some of the most complex ...
(Date:4/27/2016)... ... , ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” ... of Committee since 1987. Since then, he has served in a number of key ... for both the program and exposition committees. In his professional career, Dr. Gardner is ...
(Date:4/27/2016)... Columbia , April 27, 2016 ... "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... Anschluss an ihre Pressemitteilung vom 13. August 2015 ... hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten auf ... Kanadische Dollar zu bringen. Davon wurden 157.900.000 Einheiten ...
Breaking Biology Technology:
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... Images ( http://www.apimages.com ) - Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ... Hanover next week.   --> Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ...
(Date:3/9/2016)... -- This BCC Research report provides an overview of ... (RNA Seq) market for the years 2015, 2016 and ... data analysis, and services. Use this report ... such as RNA-Sequencing tools and reagents, RNA-Sequencing data analysis, ... segment and forecast their market growth, future trends and ...
(Date:3/3/2016)...  FlexTech, a SEMI Strategic Association Partner, awarded five ... Development, Leadership in Education, and, in a category new ... year of the FLEXI Awards and the winners ... past years . Judging was done on a ... criteria, by a panel of non-affiliated, independent, industry experts. ...
Breaking Biology News(10 mins):